Alliance Pharma (LSE:APH) Equity-to-Asset : 0.54 (As of Jun. 2023)

View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Equity-to-Asset?

Equity to Asset ratio is calculated as total stockholders equity divided by total asset. Alliance Pharma's Total Stockholders Equity for the quarter that ended in Jun. 2023 was £277.0 Mil. Alliance Pharma's Total Assets for the quarter that ended in Jun. 2023 was £513.7 Mil. Therefore, Alliance Pharma's Equity to Asset Ratio for the quarter that ended in Jun. 2023 was 0.54.

The historical rank and industry rank for Alliance Pharma's Equity-to-Asset or its related term are showing as below:

LSE:APH' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.53 Med: 0.59 Max: 0.68
Current: 0.54

During the past 13 years, the highest Equity to Asset Ratio of Alliance Pharma was 0.68. The lowest was 0.53. And the median was 0.59.

LSE:APH's Equity-to-Asset is ranked worse than
55.51% of 1088 companies
in the Drug Manufacturers industry
Industry Median: 0.59 vs LSE:APH: 0.54

Alliance Pharma Equity-to-Asset Historical Data

The historical data trend for Alliance Pharma's Equity-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Equity-to-Asset Chart

Alliance Pharma Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Equity-to-Asset

Get a 7-Day Free Trial

0.63

0.67

0.55

0.56

0.54

Alliance Pharma Semi-Annual Data
	Dec13	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23
Equity-to-Asset	Get a 7-Day Free Trial															0.55	0.56	0.54	0.54	0.54

Competitive Comparison of Alliance Pharma's Equity-to-Asset

For the Drug Manufacturers - Specialty & Generic subindustry, Alliance Pharma's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Alliance Pharma's Equity-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Alliance Pharma's Equity-to-Asset distribution charts can be found below:

* The bar in red indicates where Alliance Pharma's Equity-to-Asset falls into.

Alliance Pharma Equity-to-Asset Calculation

Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.

Alliance Pharma's Equity to Asset Ratio for the fiscal year that ended in Dec. 2022 is calculated as

Equity to Asset (A: Dec. 2022 )	=	Total Stockholders Equity	/	Total Assets
	=	287.661	/	537.411
	=	0.54

Alliance Pharma's Equity to Asset Ratio for the quarter that ended in Jun. 2023 is calculated as

Equity to Asset (Q: Jun. 2023 )	=	Total Stockholders Equity	/	Total Assets
	=	276.959	/	513.72
	=	0.54

Alliance Pharma (LSE:APH) Equity-to-Asset Explanation

Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.

For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.

Alliance Pharma Equity-to-Asset Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Equity-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Alliance Pharma (LSE:APH) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Equity-to-Asset

Comparable Companies

Traded in Other Exchanges

DVL:Germany

Address

Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB

Website

https://www.alliancepharmaceuticals.com

Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).